Michael Schepke, Gerhard Kleber, Dieter Nürnberg, Jörg Willert, Lydia Koch, Wilfried Veltzke‐Schlieker, Claus Hellerbrand, Johannes Kuth, Stefan Schanz, Stefan Kahl, Wolfgang E. Fleig, Tilman Sauerbruch – 30 June 2004 – In this randomized controlled multicenter trial, we compared endoscopic variceal banding ligation (VBL) with propranolol (PPL) for primary prophylaxis of variceal bleeding. One hundred fifty‐two cirrhotic patients with 2 or more esophageal varices (diameter >5 mm) without prior bleeding were randomized to VBL (n = 75) or PPL (n = 77).

Johannes Wiegand, Elmar Jäckel, Markus Cornberg, Holger Hinrichsen, Manfred Dietrich, Julian Kroeger, Wolfgang P. Fritsch, Anne Kubitschke, Nuray Aslan, Hans L. Tillmann, Michael Peter Manns, Heiner Wedemeyer – 30 June 2004 – Early treatment of acute hepatitis C infection with interferon alfa‐2b (IFN‐α‐2b) prevents chronicity in almost all patients. So far, no data are available on the long‐term outcome after interferon (IFN) therapy of acute hepatitis C.

Barry H. Rumack – 30 June 2004 – Examination of the pharmacokinetics of acetaminophen can decrease misconceptions involved in clinical evaluation. Enzyme patterns and acetaminophen levels must be related to time and known metabolic phenomena. A careful look at ethanol and nutrition, especially fasting demonstrates that therapeutic doses of acetaminophen do not place patients at a greater risk in either of these instances. An overdose of acetaminophen in a chronic alcohol abuser may result in more severe hepatotoxicity than in the nonalcoholic.

Neil Kaplowitz – 30 June 2004

Ariel E. Feldstein, Nathan W. Werneburg, Ali Canbay, Maria Eugenia Guicciardi, Steven F. Bronk, Robert Rydzewski, Laurence J. Burgart, Gregory J. Gores – 30 June 2004 – Nonalcoholic fatty liver disease (NAFLD) is a serious health problem. Although NAFLD represents a form of lipotoxicity, its pathogenesis remains poorly understood. The aim of this study was to examine the cellular mechanisms involved in free fatty acid (FFA)‐mediated hepatic lipotoxicity.

Makoto Asamoto, Naomi Hokaiwado, Toshiya Murasaki, Tomoyuki Shirai – 30 June 2004 – Connexins are subunits of gap junction channels, which allow direct transfer of ions, secondary messenger molecules, and other metabolites between contacting cells. Gap junctions are believed to be involved in tissue homeostasis, embryonic development, and control of cell proliferation. Several studies have shown that cell damage signals are transmitted through gap junctions when cells are irradiated or when cells bearing the herpes simplex virus‐thymidine kinase (HSV‐TK) gene are treated with ganciclovir.

Ruben R. Plentz, Martin Caselitz, Joerg S. Bleck, Michael Gebel, Peer Flemming, Stefan Kubicka, Michael P. Manns, K. Lenhard Rudolph – 30 June 2004 – The telomere hypothesis of cancer initiation indicates that telomere shortening initiates cancer by induction of chromosomal instability. To test whether this hypothesis applies to human hepatocellular carcinoma (HCC), we analyzed the telomere length of hepatocytes in cytological smears of fine‐needle biopsies of liver tumors from patients with cirrhosis (n = 39).

Camilla S. Graham, Michael Curry, Qi He, Nezam Afdhal, David Nunes, Catherine Fleming, Robert Horsburgh, Donald Craven, Kenneth E. Sherman, Margaret James Koziel – 30 June 2004 – Persons with human immunodeficiency virus (HIV) and hepatits C virus (HCV) coinfection are at increased risk for progression to cirrhosis compared with persons with HCV alone, but the reasons for this are unclear.

Christine Ovejero, Catherine Cavard, Axel Périanin, Theodorus Hakvoort, Jacqueline Vermeulen, Cécile Godard, Monique Fabre, Philippe Chafey, Kazuo Suzuki, Béatrice Romagnolo, Satoshi Yamagoe, Christine Perret – 30 June 2004 – To clarify molecular mechanisms underlying liver carcinogenesis induced by aberrant activation of Wnt pathway, we isolated the target genes of β‐catenin from mice exhibiting constitutive activated β‐catenin in the liver. Adenovirus‐mediated expression of oncogenic β‐catenin was used to isolate early targets of β‐catenin in the liver.

Doris B. Strader, Teresa L. Wright, David L. Thomas, Leonard B. Seeff – 30 June 2004